Table 9. MIC values for CORM-2, ciprofloxacin, cefotaxime and trimethoprim for ESBL-producing E. coli isolate 7, uropathogenic UPEC isolate 2 or non-pathogenic MG1655 in response to first-time exposure to CORM-2 and after 10 or 20 times pre-exposure to CORM-2 (250 μM) or vehicle (2.5% DMSO).
| Antibiotic susceptibility testing, MIC values | |||||
|---|---|---|---|---|---|
| First exposure CORM-2 | 10x CORM-2 | 10x vehicle | 20x CORM-2 | 20x vehicle | |
| CORM-2 (μM) | |||||
| ESBL7 | 500 | 500 | 500 | 500 | 500 |
| UPEC2 | 500 | 500 | 500 | 500 | 500 |
| MG1655 | 500 | 500 | 500 | 500 | 500 |
| Breakpointa - | |||||
| CIP (μg/ml) | |||||
| ESBL7 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| UPEC2 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 |
| MG1655 | 0.031 | 0.031 | 0.031 | 0.031 | 0.031 |
| Breakpointa 0.5/1 | |||||
| CTX (μg/ml) | |||||
| ESBL7 | >32 | >32 | >32 | >32 | >32 |
| UPEC2 | 0.062 | 0.062 | 0.062 | 0.062 | 0.062 |
| MG1655 | 0.062 | 0.062 | 0.062 | 0.062 | 0.062 |
| Breakpointa 1/2 | |||||
| TMP (μg/ml) | |||||
| ESBL7 | >32 | >32 | >32 | >32 | >32 |
| UPEC2 | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 |
| MG1655 | 0.5 | 0.5 | 0.5 | 1 | 1 |
| Breakpointa 2/4 | |||||
Abbreviations: ciprofloxacin (CIP), cefotaxime (CTX), trimethoprim (TMP)
a Clinical MIC breakpoint for Enterobacteriaceae set by the SRGA and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). S, susceptibility/ R, resistant. -, No clinical breakpoint.